Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70004 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Soon Sun Kim and 6 co-authors. Institution: Department of Gastroenterology, Ajou University School of Medicine, Suwon, South Korea. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Cancer Survivors. Cited 7 times so far (Crossref); 37 references. Funded by: Korean Association for the Study of the Liver, National Research Foundation of Korea, Ministry of Science and ICT, South Korea.
Abstract (original language)
Background and Aims This study investigated the long‐term prognosis and clinical course of patients who survived for more than 5 years after hepatocellular carcinoma (HCC) diagnosis.
Methods
This retrospective cohort study used data from the Korean National Health Insurance Service database. A total of 35,348 subjects newly diagnosed with HCC between January 2008 and December 2010 were followed up until December 2018.
Results
A total of 11,514 (32.6%) survived for 5 years after diagnosis of HCC among 35,348 patients diagnosed with HCC. Long‐term survivors (≥ 5 years) had a higher proportion of females, younger age, more frequent aetiology of hepatitis B virus, less frequent liver cirrhosis, diabetes mellitus and hypertension, and received curative treatment more frequently than nonsurvivors (< 5 years). The additional 1‐, 3‐ and 5‐year cumulative survival probabilities were 90.7%, 77.6% and 68.4% respectively. Patients who underwent curative treatment as the first treatment for HCC showed a higher additional 5‐year cumulative survival probabilities than those treated with noncurative therapy (74.5% vs. 64.2%). Among the long‐term survivors, 44.4% underwent HCC retreatment 5 years after HCC diagnosis. The additional 5‐year cumulative survival probability was 54.9% in the HCC retreatment group. The overall 5‐ and 10‐year cumulative probabilities of second primary malignancies in long‐term survivors were 15.36% and 27.54% respectively. The most frequent second primary malignancy was prostate cancer, followed by colorectal and pancreatic cancers.
Conclusion
Our study highlights that a significant proportion of patients with HCC achieve long‐term survival beyond 5 years, with favourable outcomes associated with curative treatments.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Gastroenterology, Ajou University School of Medicine, Suwon, South Korea.
- Department of Medical and Digital Engineering, Hanyang University College of Engineering, Seoul, South Korea.
- Department of Internal Medicine, Eulji University College of Medicine, Seoul, South Korea.
- Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea.
- Department of Internal Medicine, School of Medicine, Hanyang University, Seoul, South Korea.
- Department of Internal Medicine, Soonchunhyang University College of Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea.
ORCID profiles: Soon Sun Kim, Dae Won Jun
Funding
- Korean Association for the Study of the Liver
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea
- Soonchunhyang University
Cite
APA
Kim, S. S., Lee, J., Ahn, S. B., Chon, Y. E., Yoon, E., Jeong, S. W., & Jun, D. W. (2025). Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70004
Vancouver
Kim SS, Lee J, Ahn SB, Chon YE, Yoon E, Jeong SW, et al. Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70004
BibTeX
@article{Kim2025,
author = {Kim, Soon Sun and Lee, Jonghyun and Ahn, Sang Bong and Chon, Young Eun and Yoon, Eileen and Jeong, Soung Won and Jun, Dae Won},
title = {Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70004}
}
EUVIMED